Latest News
Web Date: November 1, 2006

Merck Is To Acquire Sirna

Move signals big pharma's confidence in RNAi therapeutics
Department: Business

Looking to stay on the cutting edge of drug discovery, Merck & Co. has agreed to shell out $1.1 billion for Sirna Therapeutics, a San Francisco-based biotech firm focused on drugs based on RNA interference.

Merck says Sirna's RNAi technology complements internal efforts on RNA expression that have been under way since its 2001 acquisition of Rosetta Inpharmatics. The company believes the technology combination could significantly change the way drugs are discovered and . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society